

Application No.: 09/816,839
Attorney Docket No.: TNX 00-04
Customer No.: 26839

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-18 (Canceled)

19. (Previously Amended) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which inhibits complement activation more than 50% at a molar ratio of 1:2 (antibody to C2).
20. (Previously Amended) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which inhibits both the classical and the lectin complement pathways more than 50% at a molar ratio of 1:2 (antibody to C2).
21. (Canceled)
22. (Previously Presented) The antibody of claim 19, wherein the antibody fragment is a Fab, F(ab')₂, Fv or single chain Fv.
23. (Previously Presented) The antibody of claim 19, wherein the antibody is monoclonal.
24. (Previously Presented) The monoclonal antibody of claim 23, wherein the antibody is a chimeric, deimmunized, humanized or a human antibody.
25. (Currently Amended) A monoclonal antibody designated 175-62 produced by the hybridoma cell line ~~475-62~~ and deposited under ATCC Accession Number PTA-1553.
26. (Currently Amended) A cell line that produces the monoclonal antibody designated 175-62, said cell line deposited under ATCC Accession No. PTA-1553.

Application No.: 09/816,839
Attorney Docket No.: TNX 00-04
Customer No.: 26839

27. (Previously Amended) A composition comprising the antibody of claim 19 and a pharmacologically acceptable carrier, excipient, stabilizer, or diluent.
28. (Previously Amended) A method of inhibiting complement activation comprising administering the antibody of claim 19 or claim 20.
29. (Previously Amended) A method of inhibiting the classical and lectin complement pathways comprising administering the antibody of claim 19 or claim 20.
30. (Previously Presented) The method of claim 28, wherein the inhibition of complement activation is determined *in vitro*.
31. Canceled
32. (Previously Amended) A method of treating a disease or condition that is mediated by excessive or uncontrolled activation of the complement system comprising administering, *in vivo* or *ex vivo*, the antibody of claim 19 or claim 20.
33. (Previously Presented) The method of claim 32, wherein the antibody is administered by intravenous infusion, intravenous bolus injection, intraperitoneal, intradermal, intramuscular, subcutaneous, intranasal, intratracheal, intraspinal, intracranial, or orally.
34. (Previously Presented) A diagnostic method comprising the detection of the amount of C2 or C2a present in a sample with the antibody of claim 19.
35. (Currently Amended) The diagnostic method of claim 34, wherein the antibody is the monoclonal antibody designated 175-62 and produced by the hybridoma deposited under ATCC Accession number PTA-1553.
36. (Previously Presented) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which completely inhibits complement activation at a molar ratio of 1:2 (antibody to C2).

Page 3 of 10

Application No.: 09/816,839
Attorney Docket No.: TNX 00-04
Customer No.: 26839

37. (Currently Amended) The antibody of claim 36, wherein the antibody is a monoclonal antibody designated 175-62 produced by the hybridoma cell line 475-62 and deposited under ATCC Accession Number PTA-1553.